Global Blood Therapeutics

August 28, 2018August 28, 2018

Roche Sells Cardio Antibody to GBT for Vaso-Occlusive Crises in SCD

News

Hoffmann-La Roche has sold the worldwide rights to its discontinued heart disease drug, inclacumab, to Global Blood Therapeutics (GBT) for $2 million and milestone payments. GBT plans to investigate inclacumab as ... Read more

July 5, 2018July 5, 2018

First Results from Phase 3 Trial Expected to Support FDA’s Accelerated Approval of Voxelotor for Sickle Cell

News

Once-daily treatment with voxelotor, Global Blood Therapeutics’ lead therapy candidate, can effectively increase the amount of hemoglobin in about 58% of patients with sickle cell disease (SCD) in just 12 weeks, ... Read more

January 2, 2018

Voxelotor Improves Sickle Cell Disease of 83% of Adolescents in Phase 2a Trial

News

The sickle disease of 83 percent of adolescents improved after 16 weeks of taking Global Blood Therapeutics‘ voxelotor, preliminary results of a Phase 2a clinical trial indicate. Another important finding ... Read more

November 21, 2017

Review Board Finds Global Blood’s Sickle Cell Disease Therapy Voxelotor Is Safe

News

An independent review board has found Global Blood Therapeutics’ sickle cell disease treatment voxelotor safe, and recommended that its Phase 3 clinical trial continue. The hallmark of sickle cell disease is damage to ... Read more

November 14, 2017November 14, 2017

Sickle Cell Patient with Severe Anemia Rapidly Improves with Voxelotor, Case Study Shows

News

Global Blood Therapeutics (GBT) reported a case study in which a sickle cell disease (SCD) patient was granted compassionate access to the company’s ongoing Phase 3 HOPE study of voxelotor ... Read more

July 11, 2017

Global Blood Expands Sickle Cell Study to Include Kids Ages 6-11

News

Global Blood Therapeutics has expanded its ongoing HOPE-KIDS 1 trial (NCT02850406), evaluating the investigative GBT440 in pediatric patients with sickle cell disease, to include a new single-dose cohort in younger ... Read more

June 29, 2017

European Agency Grants PRIME Access to GBT440 Therapy for Treatment of SCD

News

The European Medicines Agency (EMA) has granted GBT440 — Global Blood Therapeutics’ lead drug candidate for sickle cell disease (SCD) — access to its Priority Medicines (PRIME) program. GBT440 is an oral, ... Read more

June 23, 2016

US-based Biopharma Presents Positive Data on Potential Sickle Cell Therapy at European Hematology Congress

News

Global Blood Therapeutics, a biopharma developing novel therapeutics for the treatment of blood-based disorders, recently announced new results from its ongoing Phase 1/2 study of GBT440-001 in sickle cell disease (SCD). ... Read more

June 6, 2016June 6, 2016

GBT to Review Candidate Data for Sickle Cell on June 10 Webcast

News

Global Blood Therapeutics, a biopharma focused on the development of innovative therapeutics for the treatment of blood-based disorders such as sickle cell disease (SCD), will host an investor’s webcast at ... Read more

Pin It on Pinterest